The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.85, a high estimate of $68.00, ...

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $28.10, denoting a -0.14% change from the preceding trading day.

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Citi lowered the firm’s price target on Hims & Hers to $25 from $27 and keeps a Sell rating on the shares. The firm also added a “downside ...

Still, plenty of men ask: Do women like beards? The short answer: It depends on the woman, the man, and the style.

Shares of WW (WW) jumped after Galloway Capital Partners reported a 2.87% stake in the company and disclosed a letter sent to its CEO Tara ...

Hims & Hers (HIMS) stock in focus as a U.S. court denies injunction to continue making cheap versions of Novo Nordisk's (NVO) ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left ...

The Food and Drug Administration on Tuesday posted a warning about generic forms of a popular hair-loss medication often sold by major telehealth companies including Hims, Keeps and Ro, citing reports ...

A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...